Gossamer Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulateddeficit · Accumulatedothercomprehensiveincome (loss) · Totalstockholders'equity (deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 94,423,181 | $10 | $1,044,864 | $(1,032,223) | $(574) | $12,077 |
| Issuance of common stock in connection with a private offering, net of offering costs of $10,779 | 129,869,440 | 13 | 201,310 | — | — | 201,323 |
| Vesting of restricted stock | 55,225 | — | — | — | — | — |
| Stock-based compensation | — | — | 28,518 | — | — | 28,518 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 336,795 | — | 444 | — | — | 444 |
| Issuance of common stock for restricted stock units vested | 724,674 | — | — | — | — | — |
| Net loss | — | — | — | (179,817) | — | (179,817) |
| Other comprehensive income | — | — | — | — | 224 | 224 |
| Balance as of December 31, 2023 | 225,409,315 | $23 | $1,275,136 | $(1,212,040) | $(350) | $62,769 |
| Grant of equity option pursuant to Chiesi Collaboration Agreement | — | — | 464 | — | — | 464 |
| Stock-based compensation | — | — | 20,619 | — | — | 20,619 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 767,125 | — | 629 | — | — | 629 |
| Issuance of common stock for restricted stock units vested | 427,698 | — | — | — | — | — |
| Net loss | — | — | — | (56,528) | — | (56,528) |
| Other comprehensive income | — | — | — | — | 1,539 | 1,539 |
| Balance as of December 31, 2024 | 226,604,138 | $23 | $1,296,848 | $(1,268,568) | $1,189 | $29,492 |
| Investment in merger option through issuance of stock | 2,500,000 | 1 | 7,475 | — | — | 7,476 |
| Exercise of warrants | 1,791,823 | — | 3,655 | — | — | 3,655 |
| Exercise of stock options | 1,691,213 | — | 1,930 | — | — | 1,930 |
| Stock-based compensation | — | — | 10,555 | — | — | 10,555 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 1,089,883 | — | 840 | — | — | 840 |
| Net loss | — | — | — | (170,370) | — | (170,370) |
| Other comprehensive loss | — | — | — | — | (6,338) | (6,338) |
| Balance as of December 31, 2025 | 233,677,057 | $24 | $1,321,303 | $(1,438,938) | $(5,149) | $(122,760) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.